行情

NEO

NEO

Neogenomics
NASDAQ

实时行情|Nasdaq Last Sale

21.59
-0.29
-1.33%
盘后: 21.02 -0.57 -2.64% 19:31 01/21 EST
开盘
21.56
昨收
21.88
最高
22.25
最低
21.32
成交量
164.36万
成交额
--
52周最高
61.57
52周最低
21.32
市值
26.58亿
市盈率(TTM)
62.43
分时
5日
1月
3月
1年
5年
BRIEF-Neogenomics- On Jan 17, 2022, Kevin Johnson Provided Notice Of Resignation From Board Following Which Board Reduced Size From 9 To 8 Directors
reuters.com · 3天前
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday morning saw 454 companies set new 52-week lows.
Benzinga · 4天前
Where NeoGenomics Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over th...
Benzinga · 01/12 14:07
NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
MYERS, FL / ACCESSWIRE / January 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limi...
ACCESSWIRE · 01/11 12:00
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
Zacks.com · 2021/12/30 11:20
SkySong 的癌症研究公司、保险代理租赁
Office leasing activity continues in the Scottsdale area despite the continuing pandemic. One of the new tenants at SkySong is NeoGenomics Inc., a publicly-traded cancer research firm.
American City Business Journals · 2021/12/29 20:58
Cowen & Co. Initiates Coverage On NeoGenomics with Outperform Rating, Announces Price Target of $42
Cowen & Co. analyst Dan Brennan initiates coverage on NeoGenomics (NASDAQ:NEO) with a Outperform rating and announces Price Target of $42.
Benzinga · 2021/12/16 13:05
BRIEF-Inivata Appoints David Eberhard As Chief Medical Officer
reuters.com · 2021/12/13 12:25
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解NEO最新的财务预测,通过NEO每股收益,每股净资产,每股现金流等数据分析Neogenomics近期的经营情况,然后做出明智的投资选择。
分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

41.67%强力推荐
50.00%买入
8.33%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测NEO价格均价为48.82,最高价位60.00,最低价为41.00。
最高60.00
均价48.82
最低41.00
现价21.59
EPS
实际EPS
预期EPS
-0.08-0.010.050.11
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 427
机构持股: 1.20亿
持股比例: 97.42%
总股本: 1.23亿
类型机构数股数
增持
115
962.98万
建仓
40
115.66万
减持
118
477.45万
平仓
47
70.58万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
医疗设施与服务
-1.47%
医疗保健提供商与服务
-1.24%
高管信息
Non-Executive Chairman
Lynn Tetrault
Chief Executive Officer/Director
Mark Mallon
Chief Financial Officer
William Bonello
Corporate Executive
George Cardoza
Corporate Executive
Clive Morris
Corporate Executive
Gina Wallar
Chief Accounting Officer/Controller
Cynthia Dieter
Chief Marketing Officer
Marcus Silva
Chief Compliance Officer
Stephanie Bywater
Chief Risk Officer
Kathryn McKenzie
General Counsel/Secretary
Denise Pedulla
Other/IR Contact Officer
Douglas Brown
Other
Jennifer Balliet
Director
David Daly
Independent Director
Bruce Crowther
Independent Director
Alison Hannah
Independent Director
Kevin Johnson
Independent Director
Stephen Kanovsky
Independent Director
Michael Kelly
Independent Director
Rachel Stahler
暂无数据
NEO 简况
NeoGenomics Inc是一家癌症基因测试实验室运营商。该公司的客户包括临床和制药客户。其临床客户包括基于社区的病理学实践、肿瘤学团体、医院和学术中心。其制药客户包括向其提供测试和其他服务以支持其研究和临床试验的制药公司。该公司提供检测服务,包括细胞遗传学、荧光原位杂交 (FISH)、流式细胞术、免疫组织化学 (IHC) 和数字成像、分子检测和形态学分析。该公司的制药服务部门提供测试服务,支持其制药客户肿瘤项目从发现到商业化过程。它通过推荐用于分子筛选的最佳平台并用信息学支持其发现工具来捕获有意义的数据,从而帮助其客户开发生物标志物假设。

微牛提供NeoGenomics, Inc.(NASDAQ-NEO)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的NEO股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NEO股票基本功能。